Last reviewed · How we verify
SIMETHICONE-CELLULOSE
Simethicone-cellulose is a marketed drug designed to alleviate discomfort and bloating by breaking up gas bubbles in the stomach and intestines. Its key strength lies in its mechanism of action, which effectively targets gas-related symptoms, providing rapid relief. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | SIMETHICONE-CELLULOSE |
|---|---|
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1998 |
Approved indications
Common side effects
Key clinical trials
- Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old (PHASE3)
- The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SIMETHICONE-CELLULOSE CI brief — competitive landscape report
- SIMETHICONE-CELLULOSE updates RSS · CI watch RSS